Newsroom

Sorted by: Latest
-

Affinity Bancshares Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Affinity Bancshares, Inc. - AFBI

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Affinity Bancshares, Inc. (NasdaqCM: AFBI) to Fidelity BancShares (N.C.), Inc. Under the terms of the proposed transaction, shareholders of Affinity will receive $23.00 in cash, subject to adjustment based on Affinity’s adjusted stockholders’ equity at closing, for each share of Affinity that they o...
-

Sylmar Group Acquires Tower Water, Building the Leading Water Treatment Platform in the Northeast

SOMERSET, N.J.--(BUSINESS WIRE)--Sylmar Group, a leader in industrial water and wastewater treatment, today announced the acquisition of Tower Water, the premier provider of water treatment services in New York City. Tower Water will join the Sylmar Water Treatment family of companies, alongside EAI Water, Clearwater Industries, R2J Chemical Services, Eastern Technologies Inc. (ETI), Butler Chemical, and ProChem Water, as Sylmar continues to build its nationwide network of local, technical, and...
-

Spectora Introduces New AI Tools, Reimagining How a Home Inspection Gets Done

DENVER--(BUSINESS WIRE)--Spectora launches 3 AI tools in early access to help home inspectors finish reports on-site, never miss bookings, and run their business on real data....
-

Rupert Resources Securityholders Approve Proposed Arrangement With Agnico Eagle and Agnico Eagle Receives Conditional Listing Approval of Contingent Value Rights

TORONTO--(BUSINESS WIRE)--Rupert Resources Ltd. (TSX: RUP, OTCQX: RUPRF, FSE:R05) (“Rupert” or the “Company”) is pleased to announce that, at the special meeting of holders (“Shareholders”) of its common shares (“Shares”), holders of its options to purchase Shares (“Options”), holders of its deferred share units (“DSUs”), holders of its performance share units (“PSUs”) and holders of its restricted share units (“RSUs” and, collectively with the Shareholders, holders of Options, DSUs, PSUs and R...
-

Neuraptive Therapeutics, Inc. anuncia importantes atualizações organizacionais para apoiar avanço da empresa rumo à comercialização

CHESTERBROOK, Pensilvânia--(BUSINESS WIRE)--A Neuraptive Therapeutics anunciou hoje a designação de Ulf Wiinberg para seu Conselho Administrativo e de William "Bill" MacKenzie como Vice-Presidente Sênior de Finanças. O Sr. Wiinberg é um executivo experiente nas indústrias de biotecnologia, farmacêutica e de saúde, com uma extensa carreira internacional. Como membro do Conselho Administrativo, irá contribuir com orientação estratégica e conhecimento do setor para apoiar a estratégia de desenvolv...
-

Riassunto: Neuraptive Therapeutics, Inc. annuncia importanti aggiornamenti organizzativi per aiutare a promuovere la commercializzazione della società

CHESTERBROOK, Pa.--(BUSINESS WIRE)--Neuraptive Therapeutics oggi ha annunciato la nomina di Ulf Wiinberg al suo CdA e di William “Bill” MacKenzie a Vicepresidente senior – Finanza. Wiinberg è un dirigente di grande esperienza nei settori biotecnologico, farmaceutico e sanitario, con un'ampia carriera globale alle spalle. Come membro del CdA, Wiinberg contribuirà al successo dell'azienda con la la sua guida strategica e la sua competenza nel settore per aiutare a realizzare la strategia di svilu...
-

Neuraptive Therapeutics, Inc.宣布關鍵組織架構調整，以支援公司推進商業化進程

賓夕法尼亞州賈斯特布魯克--(BUSINESS WIRE)--(美國商業資訊)-- Neuraptive Therapeutics今日宣布任命Ulf Wiinberg為公司董事會成員，並任命William “Bill” MacKenzie為財務資深副總裁。 Wiinberg先生是一位經驗豐富的生物科技、製藥及醫療保健產業高階主管，擁有豐富的全球執業經驗。身為董事會成員，他將提供策略指導和產業專業知識，以支援公司的發展與商業化策略。 Wiinberg先生的履歷包括：2017年至2024年擔任X-Vax Technology, Inc.執行長；在此之前，他於2008年至2014年擔任Lundbeck執行長。2002年至2008年，他是Wyeth管理委員會成員，並于2002年至2005年擔任Wyeth Consumer Healthcare全球總裁，隨後擔任歐洲/中東/非洲區總裁直至2008年Wyeth被Pfizer收購。 Ulf還在多家公司的董事會擔任董事，包括總部位於比利時布魯塞爾的全球生物製藥公司UCB、瑞典隆德的Alfa Laval AB、瑞典斯德哥爾摩的SIGRID Therape...
-

Neuraptive Therapeutics, Inc.宣布关键组织架构调整，以支持公司推进商业化进程

宾夕法尼亚州切斯特布鲁克--(BUSINESS WIRE)--(美国商业资讯)-- Neuraptive Therapeutics今日宣布任命Ulf Wiinberg为公司董事会成员，并任命William “Bill” MacKenzie为财务高级副总裁。 Wiinberg先生是一位经验丰富的生物技术、制药及医疗保健行业高管，拥有丰富的全球从业经验。作为董事会成员，他将提供战略指导和行业专业知识，以支持公司的发展与商业化战略。 Wiinberg先生的履历包括：2017年至2024年担任X-Vax Technology, Inc.首席执行官；在此之前，他于2008年至2014年担任Lundbeck首席执行官。2002年至2008年，他是Wyeth管理委员会成员，并于2002年至2005年担任Wyeth Consumer Healthcare全球总裁，随后担任欧洲/中东/非洲区总裁直至2008年Wyeth被Pfizer收购。 Ulf还在多家公司的董事会担任董事，包括总部位于比利时布鲁塞尔的全球生物制药公司UCB、瑞典隆德的Alfa Laval AB、瑞典斯德哥尔摩的SIGRID Thera...
-

ニューラプティブ・セラピューティクス、商業化に向けた進展を支える主要な組織変更を発表

ペンシルベニア州チェスターブルック--(BUSINESS WIRE)--（ビジネスワイヤ） -- ニューラプティブ・セラピューティクスは、ウルフ・ウインバーグを取締役に任命し、ウィリアム（ビル）・マッケンジーを財務担当シニアバイスプレジデントとして迎え入れたと発表しました。 ウインバーグは、バイオテクノロジー、製薬、ヘルスケア業界で幅広い国際経験を積んできた経営幹部です。取締役として、ニューラプティブ・セラピューティクスの開発・商業化戦略を支えるため、戦略的な助言を行い、業界で培った専門知識を生かします。 ウインバーグは2017～2024年にX-Vax Technology, Inc.のCEOを務め、それ以前は2008～2014年にルンドベックのCEOを務めました。2002～2008年にはワイスの経営委員会のメンバーを務め、この間、2002～2005年にはワイス・コンシューマー・ヘルスケアのワールドワイドプレジデントを、2008年にワイスがファイザーに買収されるまで欧州・中東・アフリカ地域担当プレジデントを務めました。 ウインバーグは、ベルギーのブリュッセルに本社を置くグローバルバイ...
-

DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds PicS N.V. (PICS) Investors of Securities Class Action Deadline on August 4, 2026

NEW YORK--(BUSINESS WIRE)--Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against PicS N.V. (“PicS” or the “Company”) (NASDAQ: PICS) and reminds investors of the August 4, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovere...